

# PAD VOLUME I

## Table of Contents

<b>INTRODUCTION</b> .....	7
<b>THE DISEASE</b> .....	7
<b>SYMPTOMS AND CONSEQUENCES</b> .....	8
<b>INTERMITTENT CLAUDICATION IS UNCOMMON</b> .....	8
<b>PAD IS NOT ASYMPTOMATIC</b> .....	10
<b>MORTALITY</b> .....	11
<i>Heart Attack and Stroke—The Main Causes of Death</i> .....	11
<i>High Five- and 10-Year Mortality</i> .....	11
<b>AN INDICATOR OF SILENT CARDIOVASCULAR AND CEREBROVASCULAR</b>	
<b>DISEASE</b> .....	13
<b>PAD SEVERITY PREDICTS CARDIOVASCULAR MORBIDITY AND MORTALITY</b> .....	14
<b>RISK FACTORS</b> .....	15
<i>Age</i> .....	16
<i>Smoking</i> .....	17
<i>Diabetes</i> .....	17
<i>Hypertension</i> .....	18
<i>Cholesterol</i> .....	18
<i>Race</i> .....	19
<b>MULTIPLE RISK FACTORS INCREASE THE RISK</b> .....	19
<b>WOMEN AND PAD</b> .....	20
<b>DIAGNOSIS</b> .....	21
<b>DISEASE SEVERITY ASSOCIATED WITH LOWER ABI</b> .....	21
<b>PREVALENCE</b> .....	22
<b>PAD IS A SIGNIFICANT MARKET OPPORTUNITY—14 MILLION PEOPLE</b> .....	23
<i>Estimated Prevalence Based On Diabetic Population</i> .....	23
<b>PAD TO INCREASE WITH THE GRAYING OF AMERICA</b> .....	25
<b>PAD PREVALENCE COMPARED TO OTHER SERIOUS DISEASES</b> .....	25
<b>PAD IS UNDERDIAGNOSED</b> .....	26
<i>Less Than 20% of PAD Patients Estimated to Have Been Diagnosed</i> .....	27
<i>New Education and Awareness Programs Leading to Increased Numbers Diagnosed</i> .....	29
<b>TREATMENTS</b> .....	30
<i>Risk Factor Modification</i> .....	30
<i>Supervised Exercise Program</i> .....	30
<i>Drug Therapy</i> .....	31
<b>ATHEROSCLEROSIS—AN INFLAMMATORY DISEASE</b> .....	31
<i>Vulnerable Plaque</i> .....	33
<i>Blood Clots</i> .....	33
<b>ANTIHYPERTENSIVES</b> .....	34
<i>ACE Inhibitors and Angiotensin Receptor Blockers (Antagonists)</i> .....	34
<i>Angiotensin Receptor Blockers</i> .....	36
<b>DIABETIC PATIENTS</b> .....	36
<b>REDUCING THE RISK OF BLOOD CLOTS</b> .....	37
<b>LIPID REDUCTION</b> .....	39

<i>Statins</i> .....	39
Muscle Myopathy .....	40
Heart Protection Study .....	41
<i>Zetia—A New Class of Cholesterol Medication</i> .....	41
<i>Other Lipid-Lowering Agents—Fibrates and Bile Acid Sequestrants</i> .....	42
<i>Niacin</i> .....	43
<b>CHOLESTEROL REDUCTION AND VASCULAR REMODELING</b> .....	44
<b>PAD DYSLIPIDEMIA SIMILAR TO ATHEROGENIC DYSLIPIDEMIA</b> .....	46
<b>NEW OPPORTUNITIES—TARGETED DRUG THERAPY FOR PAD</b> .....	47
<b>NEW RISK FACTORS</b> .....	49
<i>Lipoprotein (a)</i> .....	49
<i>Homocysteine</i> .....	50
<i>Inflammatory Factors</i> .....	50
<i>C-Reactive Protein</i> .....	51
<b>CLAUDICATION THERAPIES</b> .....	52
<b>PROGRESSION OF PAD AND PERCENTAGE OF PATIENTS NEEDING</b>	
<b>TREATMENT</b> .....	53
<b>PAD UNDERTREATED</b> .....	54
<b>LARGE POTENTIAL MARKETS FOR DRUG THERAPY</b> .....	55
<i>Market for Claudication Therapy</i> .....	59
<i>Market for Antihypertensives</i> .....	59
<i>Market for Cholesterol-Lowering Therapy</i> .....	62
<i>Market for Antiplatelets</i> .....	65
<b>VALUATION TABLE</b> .....	69
<b>COMPANY INFORMATION AND FINANCIAL DATA (ALPHABETICAL LIST)</b> .....	71
<b>REFERENCES</b> .....	97
<b>LIST OF STUDIES/ACRONYMS</b> .....	107
<b>INDEX OF TABLES AND FIGURES</b> .....	111
<b>GLOSSARY</b> .....	117
<b>TRADEMARKS</b> .....	131
<b>DISCLOSURE STATEMENT</b> .....	133
<b>CONTACT INFORMATION</b> .....	135